22 Jul Deverra Therapeutics
Colleen Delaney, M.D., Founder and Chief Scientific Officer
Oct. 7 | 9:45am | FLW Ballroom F
Seattle, WA
(Private)
Deverra is a clinical-stage biotechnology company in Seattle developing allogeneic, off-the-shelf universal cellular immunotherapies. Deverra’s mission is to ensure that no patient is left untreated due to requirements for donor matching, complex and high cost of manufacturing, or cell therapy product availability when it is needed most. Starting from FDA-regulated pooled umbilical cord blood, Deverra leverages a proprietary stem cell expansion technology for scale followed by directed differentiation to generate many distinct immune effector cell types. This results in a diverse pipeline of therapies, including the potential for combination cellular therapy approaches. Dilanubicel, a universal allogeneic ex vivo expanded progenitor cell therapy and Deverra’s lead clinical asset, demonstrated a 95% increase in initial remission rates when used in upfront AML therapy in a global randomized controlled phase 2 trial. Based on these safety and preliminary efficacy outcomes, the FDA has granted Dilanubicel RMAT, Orphan Drug, and Fast Track special designations.
